BioPlus Acquisition Corp.

BioPlus Acquisition Corp. (Nasdaq: BIOS) is a blank-check company that completed its initial public offering in December 2021, with its final prospectus filed on Form 424B4 on December 6, 2021 (SEC accession 0001193125-21-349122). Sponsored by BioPlus Acquisition LLC, the vehicle was formed to pursue a business combination in the healthcare and life sciences sector, with a particular focus on biopharmaceutical and biotechnology targets. As with many SPACs of its vintage, BIOS entered a challenging merger environment as SPAC deal activity slowed through 2022 and 2023. For the latest transaction status, target announcement details, and full filing history on BioPlus Acquisition Corp., sign up for a SpacDesk account at spacdesk.com.